PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)

Sponsor
Chugai Pharmaceutical
Study ID
NCT00380601
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

An open-label, PhaseⅢ study to evaluate the efficacy and safety of MRA in patients with RA

Key Dates

Start date
May 31, 2006
Status verified
Dec 2009
Primary completion
Aug 31, 2008
Completion
Feb 28, 2009

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Frequency of ACR 20％ improvement at the final visit [ Time Frame: throughout study ]

Related Studies